In Silico Approach in Designing a Novel Multi-Epitope Vaccine Candidate against Non-Small Cell Lung Cancer with Overexpressed G Protein-Coupled Receptor 56.
CONCLUSION: Overall, results showed that Fvax is a potential vaccine against NSCLC. The approach of this study efficiently minimized the number of tests, cost and time required to select the best epitopes and to design a vaccine for the treatment of NSCLC.<br />.
PMID: 32856858 [PubMed - as supplied by publisher]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
More News: Allergy | Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology | Vaccines